Timber Pharmaceuticals Inc

ASE:TMBR  
0.71
-0.01 (-1.34%)
Products, Regulatory, Earnings Announcements

Timber Pharmaceuticals Reports Positive Top-Line Results From Phase 2B Control Study Evaluating Tmb-001 In Moderate To Severe Congenital Ichthyosis

Published: 10/07/2021 13:17 GMT
Timber Pharmaceuticals Inc (TMBR) - Timber Pharmaceuticals Reports Positive Top-line Results From Phase 2b Control Study Evaluating Tmb-001 in Moderate to Severe Congenital Ichthyosis.
Timber Pharmaceuticals Inc - Data Demonstrate Reduction in Targeted and Overall Severity of Ci in Patients Treated With Topical Ipeg Tmb-001.
Timber Pharmaceuticals Inc - Planning for End-of-phase 2 Meeting With FDA in Beginning of 2022.
Timber Pharmaceuticals Inc - Phase 3 Study is Expected to Begin in Q2 2022.